Version 2

Tamibarotene

Medicine

Extended indication Treatment of patients with relapsed or refractory non-APL AML (acute promyelocytenleukemie is een subtype van acute myeloïde leukemie), relapsed or re
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Tamibarotene
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication AML / MDS
Extended indication Treatment of patients with relapsed or refractory non-APL AML (acute promyelocytenleukemie is een subtype van acute myeloïde leukemie), relapsed or refractory higher-risk MDS (myelodysplastic syndrome), newly diagnosed treatment naïve AML, or transfusion dependent, lower-risk MDS.
Proprietary name Amnolake
Manufacturer Syros
Mechanism of action Receptor agonist
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)
Additional remarks Retinoic acid receptor (RAR) agonist.

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP Unknown
Orphan drug Yes
Registration phase Clinical trials
Additional remarks Fase II klinisch onderzoek

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.
References NCT02807558
Additional remarks Verschillende doseringen onderzocht

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.
References NKR; LLS.org
Additional remarks Totaal aantal AML patienten 674, 10-15% van de volwassen AML patienten heeft APL. Totaal aantal MDS patiënten betreft 695.

Expected cost per patient per year

References GoodRx.com
Additional remarks 28 dose packs (3 tablets) Xermelo 250 mg $5,300.00 in de VS.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions No

Other information